Monitor the EHA 2026 poster presentation on June 13, 2026, for additional detail on immunogenicity and potential partner interest. The next catalyst is the regulatory filing for clinical testing, no date provided. Given the early stage, this is not a near-term revenue event; the stock may see modest trading interest around the EHA presentation.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 11 $3.61entry
- T+1 · 5mo ago +0.83%α +0.29% · $3.64
- T+5 · 5mo ago −8.03%α −8.47% · $3.32
- T+20 · 4mo ago −11.36%α −13.25% · $3.20
- T+60 · 2mo ago −13.57%α −17.97% · $3.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating complete expression in human cells, immune recognition/activation, and targeted cell-killing across diverse human immune profiles. The data will be presented at EHA 2026 Congress on June 13, 2026, and the company is preparing a regulatory filing for clinical testing. This is positive but early-stage, with no revenue or timeline to clinic.
Key Facts
- EVX-04 is an off-the-shelf therapeutic vaccine for acute myeloid leukemia developed using the AI-Immunology™ platform.
- Preclinical data shows EVX-04 is successfully expressed, secreted in human cells, and induces specific immune responses and targeted cell-killing.
- Data will be presented at the EHA 2026 Congress in Stockholm, Sweden on June 13, 2026.
- The company is preparing a regulatory filing to begin clinical testing, but no timeline for an IND/CTA or first-in-human study was provided.
- Evaxion is a clinical-stage TechBio company with a market cap of ~$32M and no disclosed revenue from approved products.
Financial Impact
No financial figures disclosed. The company is pre-revenue and at the preclinical stage for EVX-04.
Risk Factors
- EVX-04 is still at the preclinical stage; clinical failure risk remains high.
- Evaxion has a small market cap (~$32M) and may require additional capital to fund clinical development.
- AML treatment landscape is competitive with existing therapies and other vaccine approaches.
- No timeline for a regulatory filing was disclosed, creating uncertainty on the next catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310196 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers